Please assess the completion status of the following clinical trial:

Trial Title: Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Patients with type 2 diabetes mellitus, diagnosed for at least 1 year at the time of the screening visit, insufficiently controlled with basal insulin + SU (≤50% max allowed dose) ±1 oral antidiabetic (OAD) drug.~* Patients who express the intention to fast during Ramadan.~* Signed informed consent.~Exclusion criteria:~* At the time of screening age \< legal age of majority.~* Glycated hemoglobin (HbA1c) at screening visit: \<7.5% or \>10%.~* Body mass index (BMI) \<20kg/m\^2.~* Treatment with basal insulin for less than 6 months prior to screening.~* Prior antidiabetic medication (basal insulin and OADs) not at stable dose (eg, same medication, frequency and \<20% dose change) in the last 8 weeks prior to screening.~* Previous treatment with short or rapid acting insulin other than for short term use (≤10 days) in relation to hospitalization or an acute illness in the last 6 months prior to screening.~* Any discontinuation from a glucagon like peptide-1 receptor agonist (GLP-1 RA) due to safety/tolerability issue or lack of efficacy.~* Patient not willing to perform self-monitored plasma glucose (SMPG) as required by protocol and to follow the instructions provided.~* Type 1, gestational or secondary diabetes.~* History of diabetic ketoacidosis.~* History of hypoglycemia unawareness.~* Any medical contraindication for sustained and safe fasting.~* Pregnant or breast-feeding women.~* Women of childbearing potential (WOCB) not protected by highly effective contraceptive method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy.~* Known hypersensitivity/intolerance to lixisenatide (Lyxumia) or any of its excipients.~* All contraindications of the comparator and protocol mandated background therapies or warning/precaution of use (when appropriate) as displayed in the respective National Product Labeling.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lyxumia (Type: EXPERIMENTAL): Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
- Sulfonylurea (Type: ACTIVE_COMPARATOR): Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.

Based on this trial design, predict the completion outcome and termination type (if applicable).